A Live Attenuated Dengue Virus Vaccine (Dengvaxia) is Suppressed in Individuals with Immunity to Serotype 4

Clicks: 9
ID: 337653
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #492 of 503 articles by views in The Journal of infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 503 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Dengvaxia® was the first live attenuated tetravalent dengue virus (DENV) vaccine to be tested and approved for use in people. While Dengvaxia was designed to be tetravalent, in humans, the vaccine performed like a monovalent DENV4 vaccine because the DENV4 vaccine virus replicated better than other vaccine serotypes. Dengvaxia® was safe and efficacious in children who were DENV-immune at baseline and contraindicated for use in DENV-naïve children. METHODS: When Dengvaxia® was rolled out as a pediatric vaccine in the Philippines in 2016, we established a prospective cohort to assess vaccine performance by baseline dengue serostatus. Here we report on how baseline monotypic immunity to each serotype (reflecting one past DENV infection) impacted Dengvaxia® responses. RESULTS: We observed that in children with baseline immunity to DENV1, 2 or 3, the vaccine stimulated a secondary serotype cross-neutralizing Ab response, which likely explains the overall favorable performance of the vaccine in seropositive children enrolled in phase 3 trials. We observed a high frequency (61%) of vaccine suppression among DENV4 monotypic immune children. CONCLUSIONS: Our results confirm the replication dominance of the DENV4 vaccine component in Dengvaxia® and directly implicate pre-existing DENV4 immunity in the suppression of the vaccine. Our results have broader implications for evaluating the performance of other DENV vaccines in seropositive individuals.
Reference Key
openalex_W7224125969 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Cameron Adams, Lindsay C. Dahora, Laura White, Ruby Shah, Lakshmanane Premkumar, Jedas Veronica Daag, Kristal An Agrupis, Maria Vinna Crisostomo, Michelle C. Ylade, Jacqueline L. Deen, Ana Lena Lopez, Aravinda M. de Silva
Are you one of these authors? Claim your profile
Journal The Journal of infectious diseases
Year 2026
DOI
10.1093/infdis/jiag522
URL
https://doi.org/10.1093/infdis/jiag522
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.